XL-protein

Transforming treatment with
Long Lasting Solutions

XL-protein GmbH offers cutting-edge half-life extension solutions through our proprietary PASylation technology, a powerful alternative to PEGylation and other pharmacokinetic optimization methods. By genetically fusing or chemical coupling of unstructured, biodegradable PAS amino acid sequences to your therapeutic proteins or peptides, we significantly enhance their plasma half-life and bioavailability—without compromising bioactivity in vivo or safety. Accelerate your drug development journey with innovative, next-generation half-life extension designed for the demands of modern biopharmaceuticals.

Technology

PASylation® is a superior alternative to PEGylation which enables second generation biopharmaceuticals with extended plasma half-life and enhanced action. XL-protein’s technology allows a less frequent and lower dosing together with better tolerability, thus making treatment cheaper and supporting patient compliance and safety.

Learn more

Partnering

With its strong proprietary technology position, including a broad basis of preclinical data, XL-protein focuses at the preclinical as well clinical development of PASylated proteins in several disease areas. To uncover the full potential of the PASylation technology XL-protein offers licensing opportunities on several levels.

Learn more